Apotex Is Latest To Accuse Amarin Of ‘Freezing Out’ Vascepa Competition
Becomes Fourth Antitrust Suit Alleging Amarin Has ‘Deviated From Industry Practice’
Apotex is the latest generics manufacturer that feels Amarin has engineered a “systematic effort to ensure that no other company could manufacture the generic version of its product,” Vascepa, by locking up API supply, with the Canadian firm taking legal action in a bid to bring the originator’s alleged conduct to a halt.
